NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction - PubMed (original) (raw)

NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction

S S Makarov. Arthritis Res. 2001.

Abstract

The transcription factor NF-kappa B has been well recognized as a pivotal regulator of inflammation in rheumatoid arthritis (RA), but recent developments revealed a broad involvement of NF-kappa B in other aspects of RA pathology, including development of T helper 1 responses, activation, abnormal apoptosis and proliferation of RA fibroblast-like synovial cells, and differentiation and activation of bone resorbing activity of osteoclasts. In agreement with this, studies in animal models of RA have demonstrated the high therapeutic efficacy of specific inhibitors of NF-kappa B pathway, indicating the feasibility of anti-NF-kappa B therapy for human disease.

PubMed Disclaimer

Figures

Figure 1

Inducers and targets of NF-κB. bFGF, Basic fibroblast growth factor; CD40L, CD40 ligand; COX-2, cyclooxygenase-2; GM-CSF, granulocyte-macrophage colony-stimulating factor; iNOS, inducible nitric oxide synthetase; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; RANKL, receptor activator of NF-κB ligand; TRANCE, TNF-related activation-induced cytokine; VEGF, vascular endothelial growth factor.

Similar articles

• Amplification of the synovial inflammatory response through activation of mitogen-activated protein kinases and nuclear factor kappaB using ligation of CD40 on CD14+ synovial cells from patients with rheumatoid arthritis.
  Harigai M, Hara M, Kawamoto M, Kawaguchi Y, Sugiura T, Tanaka M, Nakagawa M, Ichida H, Takagi K, Higami-Ohsako S, Shimada K, Kamatani N. Harigai M, et al. Arthritis Rheum. 2004 Jul;50(7):2167-77. doi: 10.1002/art.20340. Arthritis Rheum. 2004. PMID: 15248214
• Gadd45beta deficiency in rheumatoid arthritis: enhanced synovitis through JNK signaling.
  Svensson CI, Inoue T, Hammaker D, Fukushima A, Papa S, Franzoso G, Schett G, Corr M, Boyle DL, Firestein GS. Svensson CI, et al. Arthritis Rheum. 2009 Nov;60(11):3229-40. doi: 10.1002/art.24887. Arthritis Rheum. 2009. PMID: 19877043 Free PMC article.
• Regulation of apoptosis and inflammatory responses by insulin-like growth factor binding protein 3 in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis.
  Lee HS, Woo SJ, Koh HW, Ka SO, Zhou L, Jang KY, Lim HS, Kim HO, Lee SI, Park BH. Lee HS, et al. Arthritis Rheumatol. 2014 Apr;66(4):863-73. doi: 10.1002/art.38303. Arthritis Rheumatol. 2014. PMID: 24757139
• Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis.
  Magalhães R, Stiehl P, Morawietz L, Berek C, Krenn V. Magalhães R, et al. Virchows Arch. 2002 Nov;441(5):415-27. doi: 10.1007/s00428-002-0702-1. Epub 2002 Nov 5. Virchows Arch. 2002. PMID: 12447670 Review.
• [The treatment of rheumatoid arthritis with NF-kappaB inhibitors].
  Jimi E, Nakamura I. Jimi E, et al. Nihon Rinsho. 2005 Sep;63(9):1627-32. Nihon Rinsho. 2005. PMID: 16164222 Review. Japanese.

Cited by

• Clo-miR-14: a medicinally valued spice-derived miRNA with therapeutic implications in rheumatoid arthritis.
  Sarkar A, Saquib M, Chakraborty D, Mann S, Malik S, Agnihotri P, Joshi L, Malhotra R, Biswas S. Sarkar A, et al. Biosci Rep. 2024 Sep 25;44(9):BSR20240311. doi: 10.1042/BSR20240311. Biosci Rep. 2024. PMID: 39193714 Free PMC article.
• CLK2 mediates IκBα-independent early termination of NF-κB activation by inducing cytoplasmic redistribution and degradation.
  Li SZ, Shu QP, Zhou HM, Liu YY, Fan MQ, Liang XY, Qi LZ, He YN, Liu XY, Du XH, Huang XC, Chen YZ, Du RL, Liang YX, Zhang XD. Li SZ, et al. Nat Commun. 2024 May 9;15(1):3901. doi: 10.1038/s41467-024-48288-z. Nat Commun. 2024. PMID: 38724505 Free PMC article.
• Medical treatment of osteoarthritis: botanical pharmacologic aspect.
  Park J, Lee SW. Park J, et al. J Rheum Dis. 2024 Apr 1;31(2):68-78. doi: 10.4078/jrd.2023.0084. Epub 2024 Feb 1. J Rheum Dis. 2024. PMID: 38559799 Free PMC article. Review.
• An Overview of Therapeutic Targeting of Nrf2 Signaling Pathway in Rheumatoid Arthritis.
  Saha S. Saha S. ACS Omega. 2024 Feb 20;9(9):10049-10057. doi: 10.1021/acsomega.4c00163. eCollection 2024 Mar 5. ACS Omega. 2024. PMID: 38463248 Free PMC article. Review.
• NF-κB in biology and targeted therapy: new insights and translational implications.
  Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, Zeng C, Zhou T, Zhang J. Guo Q, et al. Signal Transduct Target Ther. 2024 Mar 4;9(1):53. doi: 10.1038/s41392-024-01757-9. Signal Transduct Target Ther. 2024. PMID: 38433280 Free PMC article. Review.

References

1. 1. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–1071. - PubMed
2. 1. Tak PP, Firestein GS. NF-kappa B: a key role in inflammatory diseases. J Clin Invest. 2001;107:7–11. - PMC - PubMed
3. 1. Makarov SS. NF-kappa B as a therapeutic target in chronic inflammation: recent advances. Mol Med Today. 2000;6:441–448. - PubMed
4. 1. Baldwin AS., Jr The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–683. - PubMed
5. 1. Karin M, Ben Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kappa B activity. Annu Rev Immunol. 2000;18:621–663. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • BioMed Central
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information